Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany
- 17 April 2008
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 24 (6), 1743-1753
- https://doi.org/10.1185/03007990802124889
Abstract
Objective: To investigate the economic impact of micafungin (MICA) for treatment of invasive candidiasis and candidaemia (systemic Candida infections), a health economic analysis was conducted comparing MICA with liposomal amphotericin B (L-AMB). Research design and methods: The model was based on a phase III, randomised, double-blind, clinical trial which compared MICA with L-AMB. The model entailed a period of 14–20 weeks starting from initiation of treatment and was analysed from a German hospital perspective. Main outcome measures: The main outcome measures were defined as the percentage of patients achieving clinical and mycological response after initial treatment and who were alive at the end of the study (EOS), and the total treatment-associated costs over the study period. Results: The health economic analysis shows that with MICA, 52.9 % of patients are successfully treated and were alive at EOS compared to 49.1 % for L-AMB. In addition, MICA has, on average, lower treatment-associated costs than L-AMB with [euro]43 243 and [euro]49 216 per patient, respectively. Because the costs are lower and the effectiveness is higher for MICA in comparison with L-AMB, MICA is more cost-effective than L-AMB. However, the results of the probabilistic sensitivity analysis show that the differences cannot be considered significant due to a large variance, although MICA remained the most cost-effective option throughout the one-way sensitivity analyses. Conclusions: The lower costs and higher effectiveness reported for MICA versus L-AMB in this analysis indicate that MICA may be a more cost-effective therapy in the treatment of invasive candidiasis and candidaemia when compared with L-AMB.Keywords
This publication has 15 references indexed in Scilit:
- Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trialThe Lancet, 2007
- Empirical Anti-Candida Therapy among Selected Patients in the Intensive Care Unit: A Cost-Effectiveness AnalysisAnnals of Internal Medicine, 2005
- Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital MortalityAntimicrobial Agents and Chemotherapy, 2005
- Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance StudyClinical Infectious Diseases, 2004
- The Epidemiology of Sepsis in the United States from 1979 through 2000New England Journal of Medicine, 2003
- Comparison of Caspofungin and Amphotericin B for Invasive CandidiasisNew England Journal of Medicine, 2002
- The Direct Cost and Incidence of Systemic Fungal InfectionsValue in Health, 2002
- Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 1999
- A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patientsBritish Journal of Haematology, 1997
- Management of Invasive Candidal Infections: Results of a Prospective, Randomized, Multicenter Study of Fluconazole Versus Amphotericin B and Review of the LiteratureClinical Infectious Diseases, 1996